| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
101,390,000 |
| Market
Cap: |
1.64(B) |
| Last
Volume: |
668,805 |
Avg
Vol: |
666,996 |
| 52
Week Range: |
$12.32 - $16.78 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
664,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$8,468,005 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
12 |
| Total Shares Sold |
0 |
0 |
10,994 |
10,994 |
| Total Sell Value |
$0 |
$0 |
$153,810 |
$153,810 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Brinkley David L |
Head of Business Dev. |
• – – |
2009-09-15 |
4 |
S |
$17.86 |
$160,708 |
D/D |
(9,000) |
14,207 |
|
- |
|
| Brinkley David L |
Head of Business Dev. |
• – – |
2009-09-15 |
4 |
OE |
$8.53 |
$76,725 |
D/D |
9,000 |
23,207 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2009-09-13 |
4 |
D |
$18.20 |
$81,318 |
D/D |
(4,468) |
91,864 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2009-08-20 |
4 |
D |
$15.65 |
$16,761 |
D/D |
(1,071) |
102,744 |
|
- |
|
| Levine Arnold J |
Director |
– • – |
2009-06-15 |
5 |
GD |
$0.00 |
$0 |
D/D |
63,967 |
12,000 |
|
- |
|
| Brinkley David L |
Head of Business Dev.Officer |
• – – |
2009-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,413 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2009-05-20 |
4 |
D |
$14.06 |
$18,939 |
D/D |
(1,347) |
97,679 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2009-05-20 |
4 |
D |
$14.06 |
$32,380 |
D/D |
(2,303) |
118,707 |
|
- |
|
| Mammen Mathai |
SVP, Research & Early Clin Dev |
• – – |
2009-05-20 |
4 |
D |
$14.06 |
$15,058 |
D/D |
(1,071) |
103,815 |
|
- |
|
| Blum Leonard M |
Sr VP, Chief Comm. Officer |
• – – |
2009-05-20 |
4 |
D |
$14.06 |
$15,269 |
D/D |
(1,086) |
124,449 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2009-05-20 |
4 |
D |
$14.06 |
$13,301 |
D/D |
(946) |
228,744 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2009-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
245,397 |
|
- |
|
| Young William D |
Director |
– • – |
2009-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
12,000 |
|
- |
|
| Whitesides George M |
Director |
– • – |
2009-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
549,419 |
|
- |
|
| Waltrip William H |
Director |
– • – |
2009-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
12,000 |
|
- |
|
| Levine Arnold J |
Director |
– • – |
2009-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
75,967 |
|
- |
|
| Malkiel Burton G |
Director |
– • – |
2009-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
12,000 |
|
- |
|
| Gunderson Robert V Jr |
Director |
– • – |
2009-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
59,396 |
|
- |
|
| Drazan Jeffrey M |
Director |
– • – |
2009-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
39,866 |
|
- |
|
| Aguiar Michael W |
Sr VP, Chief Financial Officer |
• – – |
2009-03-20 |
4 |
A |
$0.00 |
$0 |
D/D |
37,000 |
99,026 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2009-03-20 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
121,010 |
|
- |
|
| Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
• – – |
2009-03-20 |
4 |
A |
$0.00 |
$0 |
D/D |
37,000 |
229,690 |
|
- |
|
| Mammen Mathai |
Senior VP, Research |
• – – |
2009-03-20 |
4 |
A |
$0.00 |
$0 |
D/D |
37,000 |
104,886 |
|
- |
|
| Blum Leonard M |
Sr VP, Chief Comm. Officer |
• – – |
2009-03-20 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
125,535 |
|
- |
|
| Blum Leonard M |
Sr VP, Chief Comm. Officer |
• – – |
2009-02-20 |
4 |
D |
$14.87 |
$21,725 |
D/D |
(1,461) |
90,535 |
|
- |
|
704 Records found
|
|
Page 24 of 29 |
|
|
0.06 (0.37%) 
